Asset
ENVUDEUCITINIB
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06588738 | phase3 | completed | 2024-08-20 | 2025-09-23 | Alumis Inc | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 |
| NCT06586112 | phase3 | completed | 2024-07-25 | 2025-09-19 | Alumis Inc | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis |
| NCT05600036 | phase2 | completed | 2022-09-27 | 2023-06-29 | Alumis Inc | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis |
| NCT06952634 | phase1 | completed | 2025-04-29 | 2026-03-24 | Alumis Inc | An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage |
| NCT06962774 | phase1 | completed | 2025-04-23 | 2025-08-01 | Alumis Inc | An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function |
FDA applications (0)
This company has no applications containing this asset.